Document is current
Any future updates will be listed below
-
Authors
Thomas, Chloe https://orcid.org/0000-0001-8704-3262
Heathcote, Laura
Sun, Yuxiao https://orcid.org/0009-0007-9862-0038
Callister, Matthew E. J. https://orcid.org/0000-0001-8157-0803
Kitt, Jessica
Rossi, Sabrina H.
Shinkins, Bethany https://orcid.org/0000-0001-5350-1018
Usher-Smith, Juliet A. https://orcid.org/0000-0002-8501-2531
Whyte, Sophie https://orcid.org/0000-0002-7963-2523
Stewart, Grant D. https://orcid.org/0000-0003-3188-9140
,
Godoy, Angela
Burge, Sarah W.
Farquhar, Fiona
Rogerson, Suzanne
Cartledge, Jon
Kimuli, Michael
Burbidge, Simon
Caglic, Iztok
Collins, Emma
Crosbie, Philip A. J.
Iball, Gareth R.
Masson, Golnessa
Ward, Matthew
Eckert, Claire
Fraser, Sheila
Hancock, Neil
Marshall, Catriona
Neal, Richard D.
Smith, Andrew
Simmonds, Irene
Wallace, Tom
-
Funding
Funding for this research was provided by:
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
Yorkshire Cancer Research (L403C)
- License Information
-
More Information
Article History
Received: 3 September 2024
Revised: 14 April 2025
Accepted: 24 April 2025
First Online: 14 May 2025
Competing interests
: G.D.S. has received educational grants from AstraZeneca; consultancy fees from Evinova; travel expenses from MSD; he is Clinical lead (urology) National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. All other authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. YKST was approved by the North West-Preston Research Ethics Committee (21/NW/0021), and the Health Research Authority on 3 February 2021. Informed consent was obtained from all participants in YKST.
